Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Receivables - Other: 2017-2023

Historic Receivables - Other for Cidara Therapeutics (CDTX) over the last 3 years, with Mar 2023 value amounting to $20.0 million.

  • Cidara Therapeutics' Receivables - Other rose 132.56% to $20.0 million in Q1 2023 from the same period last year, while for Mar 2023 it was $20.0 million, marking a year-over-year increase of 132.56%. This contributed to the annual value of $5.6 million for FY2022, which is 100.00% up from last year.
  • As of Q1 2023, Cidara Therapeutics' Receivables - Other stood at $20.0 million, which was up 257.14% from $5.6 million recorded in Q4 2022.
  • In the past 5 years, Cidara Therapeutics' Receivables - Other registered a high of $20.0 million during Q1 2023, and its lowest value of $2.8 million during Q4 2021.
  • For the 3-year period, Cidara Therapeutics' Receivables - Other averaged around $6.6 million, with its median value being $4.3 million (2022).
  • As far as peak fluctuations go, Cidara Therapeutics' Receivables - Other plummeted by 74.77% in 2021, and later spiked by 132.56% in 2023.
  • Quarterly analysis of 4 years shows Cidara Therapeutics' Receivables - Other stood at $11.1 million in 2020, then plummeted by 74.77% to $2.8 million in 2021, then skyrocketed by 100.00% to $5.6 million in 2022, then skyrocketed by 132.56% to $20.0 million in 2023.
  • Its Receivables - Other was $20.0 million in Q1 2023, compared to $5.6 million in Q4 2022 and $4.5 million in Q3 2022.